Perioperative Outcomes of a Hydrocortisone Protocol after Endonasal Surgery for Pituitary Adenoma Resection

Abstract

Introduction In pituitary adenomas (PAs), the use of postoperative steroid supplementation remains controversial, as it reduces peritumoral edema and sinonasal complaints but disrupts the detection of adrenal insufficiency (AI). It is unclear whether postoperative cortisol supplementation has a measurable effect on improving outcomes in patients with pituitary adenoma undergoing endoscopic transsphenoidal surgery (ETS). The objective of the study was to evaluate a postoperative steroid treatment protocol on various surgical outcomes in patients with PA undergoing ETS.

Methods A retrospective cohort study was performed for patients undergoing ETS from 2005 to 2020 for PA at a single tertiary academic center. Patients were divided into two groups: those managed by a routine postoperative glucocorticoid supplementation protocol (steroid protocol) and those who received supplementation based on postoperative cortisol laboratory assessment (steroid sparing protocol). Management was otherwise the same between groups. Evaluation of length of stay (LOS), sinonasal outcomes, 30-day readmission, and perioperative complications, including AI, were performed.

Results Among 535 patients, 21% (n = 111) received postoperative steroids, while the remainder (n = 424) did not. There were no differences in mean LOS (3 vs. 3 days, p = 0.72), sinonasal complaints (27 vs. 19%, p = 0.12), 30-day readmission (5% vs. 5%, p = 0.44), and perioperative complications (5 vs. 5%, p = 0.79) between both the groups. A multivariate model supported that both groups were comparable in predicting LOS, 30-day readmission, and complications. No reduction in readmission for AI was seen.

Conclusion Routine administration of postoperative glucocorticoids did not significantly improve patient outcomes in patients with PA who underwent ETS.

Keywords

pituitary - adenoma - tumor - cortisol - adrenal insufficiency - adrenal crisis - hydrocortisone - hypothalamic–pituitary–adrenal axis - outcome

Publication History

Received: 19 April 2021

Accepted: 01 July 2021

Article published online:
27 September 2021

• References

• 1 Fernández-Balsells MM, Murad MH, Barwise A. et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96 (04) 905-912
• 2 Gittleman H, Ostrom QT, Farah PD. et al. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. J Neurosurg 2014; 121 (03) 527-535
• 3 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101 (03) 613-619
• 4 Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999; 28 (01) 81-117 , vi
• 5 Gsponer J, De Tribolet N, Déruaz JP. et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999; 78 (04) 236-269
• 6 Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe H-J, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156 (02) 203-216
• 7 Ostrom QT, Cioffi G, Gittleman H. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-oncol 2019; 21 (Suppl. 05) v1-v100
• 8 Little AS, Kelly DF, White WL. et al; TRANSSPHER Study Group. Results of a prospective multicenter controlled study comparing surgical outcomes of microscopic versus fully endoscopic transsphenoidal surgery for nonfunctioning pituitary adenomas: the Transsphenoidal Extent of Resection (TRANSSPHER) Study. J Neurosurg 2019; 132 (04) 1043-1053
• 9 Webb SM, Rigla M, Wägner A, Oliver B, Bartumeus F. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 1999; 84 (10) 3696-3700
• 10 Buttan A, Mamelak AN. Endocrine outcomes after pituitary surgery. Neurosurg Clin N Am 2019; 30 (04) 491-498
• 11 Fatemi N, Dusick JR, Mattozo C. et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 2008; 63 (04) 709-718 , discussion 718–719
• 12 Jahangiri A, Wagner JR, Han SW. et al. Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis. J Neurosurg 2016; 124 (03) 589-595
• 13 Tohti M, Li J, Zhou Y, Hu Y, Yu Z, Ma C. Is peri-operative steroid replacement therapy necessary for the pituitary adenomas treated with surgery? A systematic review and meta analysis. PLoS One 2015; 10 (03) e0119621
• 14 Munro V, Tugwell B, Doucette S, Clarke DB, Lacroix A, Imran SA. Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. Clin Endocrinol (Oxf) 2016; 85 (02) 216-222
• 15 Burgers AMG, Kokshoorn NE, Pereira AM. et al. Low incidence of adrenal insufficiency after transsphenoidal surgery in patients with acromegaly: a long-term follow-up study. J Clin Endocrinol Metab 2011; 96 (07) E1163-E1170
• 16 Salem M, Tainsh Jr. REJ, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994; 219 (04) 416-425
• 17 Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002; 87 (06) 2745-2750
• 18 Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ. Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation. J Neurosurg 2009; 111 (03) 540-544
• 19 Marko NF, Hamrahian AH, Weil RJ. Immediate postoperative cortisol levels accurately predict postoperative hypothalamic-pituitary-adrenal axis function after transsphenoidal surgery for pituitary tumors. Pituitary 2010; 13 (03) 249-255
• 20 Cozzi R, Lasio G, Cardia A, Felisati G, Montini M, Attanasio R. Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas. J Endocrinol Invest 2009; 32 (05) 460-464
• 21 Liamis G, Milionis HJ, Elisaf M. Endocrine disorders: causes of hyponatremia not to neglect. Ann Med 2011; 43 (03) 179-187
• 22 McLaughlin N, Cohan P, Barnett P, Eisenberg A, Chaloner C, Kelly DF. Early morning cortisol levels as predictors of short-term and long-term adrenal function after endonasal transsphenoidal surgery for pituitary adenomas and Rathke's cleft cysts. World Neurosurg 2013; 80 (05) 569-575
• 23 Borg H, Siesjö P, Kahlon B, Fjalldal S, Erfurth EM. Perioperative serum cortisol levels in ACTH sufficient and ACTH deficient patients during transsphenoidal surgery of pituitary adenoma. Endocrine 2018; 62 (01) 83-89
• 24 Pecoraro NC, Heiferman DM, Martin B. et al. Lower-dose perioperative steroid protocol during endoscopic endonasal pituitary adenoma resection. Surg Neurol Int 2019; 10: 52
• 25 Mizutani K, Toda M, Kikuchi R, Uchida H, Yoshida K. Steroid psychosis caused by perioperative steroid replacement for pituitary adenoma: a case report. Keio J Med 2015; 64 (01) 11-15
• 26 Peacey SR, Guo CY, Robinson AM. et al. Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf) 1997; 46 (03) 255-261
• 27 Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16 (04) 505-511
• 28 Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med 2018; 379 (26) 2547-2556
• 29 Zueger T, Kirchner P, Herren C. et al. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 2012; 97 (10) E1938-E1942
• 30 Chacko SR, Abraham AP, Asha HS, Kapoor N, Rajaratnam S, Chacko AG. Selective perioperative steroid supplementation protocol in patients undergoing endoscopic transsphenoidal surgery for pituitary adenomas. Acta Neurochir (Wien) 2020; 162 (10) 2381-2388
• 31 Bhansali A, Dutta P, Bhat MH, Mukherjee KK, Rajput R, Bhadada S. Rational use of glucocorticoid during pituitary surgery–a pilot study. Indian J Med Res 2008; 128 (03) 294-299
• 32 Regan J, Watson J. Selective use of peri-operative steroids in pituitary tumor surgery: escape from dogma. Front Endocrinol (Lausanne) 2013; 4 (MAR): 30
• 33 Wentworth JM, Gao N, Sumithran KP. et al. Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary. Clin Endocrinol (Oxf) 2008; 68 (01) 29-35
• 34 Sterl K, Thompson B, Goss CW. et al. Withholding perioperative steroids in patients undergoing transsphenoidal resection for pituitary disease: randomized prospective clinical trial to assess safety. Neurosurgery 2019; 85 (02) E226-E232
• 35 Luginbuhl AJ, Campbell PG, Evans J, Rosen M. Endoscopic repair of high-flow cranial base defects using a bilayer button. Laryngoscope 2010; 120 (05) 876-880
• 36 Chaskes MB, Khoury T, Chitguppi C. et al. A single layer synthetic dural substitute inlay is an effective sellar reconstruction technique in endoscopic transsphenoidal pituitary surgery. J Neurol Surg B Skull Base 2020; DOI: 10.1055/s-0040-1721822.
• 37 Kristof RA, Wichers M, Haun D, Redel L, Klingmüller D, Schramm J. Peri-operative glucocorticoid replacement therapy in transsphenoidal pituitary adenoma surgery: a prospective controlled study. Acta Neurochir (Wien) 2008; 150 (04) 329-335 , discussion 335